AstraZeneca Lupus Drug Anifrolumab Impresses In Mid-Stage Trial

AstraZeneca's anifrolumab targets inflammation-related protein called type 1 interferon (IFN) receptor, which plays a central role in lupus. Phase II testing showed promising results.